World Health Organization: Cancer Today. Gco.iarc.fr. 2022. International Agency for Research on Cancer. https://gco.iarc.fr/today/home.

Ghosh A, Wang X, Klein E and Heston WDW: Novel role of prostate-specific membrane antigen in suppressing prostate cancer invasiveness. Cancer Res. 65:727–731. 2005.PubMed/NCBI

EAU Guidelines. EAU Annual Congress Amsterdam 2022. ISBN 978-94-92671-16-5.

Trabulsi EJ, Rumble RB, Jadvar H, Hope T, Pomper M, Turkbey B, Rosenkrantz AB, Verma S, Margolis DJ, Froemming A, et al: Optimum imaging strategies for advanced prostate cancer: ASCO guideline. J Clin Oncol. 38:1963–1996. 2020.PubMed/NCBI View Article : Google Scholar

Parker C, Castro E, Fizazi K, Heidenreich A, Ost P, Procopio G, Tombal B and Gillessen S: ESMO Guidelines Committee. Electronic address: simpleclinicalguidelines@esmo.org. Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 31:1119–1134. 2020.PubMed/NCBI View Article : Google Scholar

Lowrance WT, Breau RH, Chou R, Chapin BF, Crispino T, Dreicer R, Jarrard DF, Kibel AS, Morgan TM, Morgans AK, et al: Advanced prostate cancer: AUA/ASTRO/SUO guideline PART I. J Urol. 205:14–21. 2021.PubMed/NCBI View Article : Google Scholar

Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, Collaco-Moraes Y, Ward K, Hindley RG, Freeman A, et al: Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): A paired validating confirmatory study. Lancet. 389:815–822. 2017.PubMed/NCBI View Article : Google Scholar

Somford DM, Hamoen EH, Fütterer JJ, van Basten JP, Hulsbergen-van de Kaa CA, Vreuls W, van Oort IM, Vergunst H, Kiemeney LA, Barentsz JO and Witjes JA: The predictive value of endorectal 3 Tesla multiparametric magnetic resonance imaging for extraprostatic extension in patients with low, intermediate and high risk prostate cancer. J Urol. 190:1728–1734. 2013.PubMed/NCBI View Article : Google Scholar

Kalapara AA, Nzenza T, Pan HYC, Ballok Z, Ramdave S, O'Sullivan R, Ryan A, Cherk M, Hofman MS, Konety BR, et al: Detection and localisation of primary prostate cancer using ⁶⁸gallium prostate-specific membrane antigen positron emission tomography/computed tomography compared with multiparametric magnetic resonance imaging and radical prostatectomy specimen pathology. BJU Int. 126:83–90. 2020.PubMed/NCBI View Article : Google Scholar

Peng L, Li J, Meng C, Li J, You C, Tang D, Wei T, Xiong W and Li Y: Can ⁶⁸Ga-prostate specific membrane antigen positron emission tomography/computerized tomography provide an accurate lymph node staging for patients with medium/high risk prostate cancer? A diagnostic meta-analysis. Radiat Oncol. 15(227)2020.PubMed/NCBI View Article : Google Scholar

Wu H, Xu T, Wang X, Yu YB, Fan ZY, Li DX, Luo L, Yang XC, Jiao W and Niu HT: Diagnostic performance of ⁶⁸gallium labelled prostate-specific membrane antigen positron emission tomography/computed tomography and magnetic resonance imaging for staging the prostate cancer with intermediate or high risk prior to radical prostatectomy: A systematic review and meta-analysis. World J Mens Health. 38:208–219. 2020.PubMed/NCBI View Article : Google Scholar

Herlemann A, Wenter V, Kretschmer A, Thierfelder KM, Bartenstein P, Faber C, Gildehaus FJ, Stief CG, Gratzke C and Fendler WP: ⁶⁸Ga-PSMA positron emission tomography/computed tomography provides accurate staging of lymph node regions prior to lymph node dissection in patients with prostate cancer. Eur Urol. 70:553–557. 2016.PubMed/NCBI View Article : Google Scholar

Hope TA, Eiber M, Armstrong WR, Juarez R, Murthy V, Lawhn-Heath C, Behr SC, Zhang L, Barbato F, Ceci F, et al: Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: A multicenter prospective phase 3 imaging trial. JAMA Oncol. 7:1635–1642. 2021.PubMed/NCBI View Article : Google Scholar

Yaxley JW, Raveenthiran S, Nouhaud FX, Samartunga H, Yaxley AJ, Coughlin G, Delahunt B, Egevad L, McEwan L and Wong D: Outcomes of primary lymph node staging of intermediate and high risk prostate cancer with ⁶⁸Ga-PSMA positron emission tomography/computerized tomography compared to histological correlation of pelvic lymph node pathology. J Urol. 201:815–820. 2019.PubMed/NCBI View Article : Google Scholar

van Kalmthout LWM, van Melick HHE, Lavalaye J, Meijer RP, Kooistra A, de Klerk JMH, Braat AJAT, Kaldeway HP, de Bruin PC, de Keizer B and Lam MGEH: Prospective validation of gallium-68 prostate specific membrane antigen-positron emission tomography/computerized tomography for primary staging of prostate cancer. J Urol. 203:537–545. 2020.PubMed/NCBI View Article : Google Scholar

Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, Rutherford N, Martin JM, Frydenberg M, Shakher R, et al: Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): A prospective, randomised, multicentre study. Lancet. 395:1208–1216. 2020.PubMed/NCBI View Article : Google Scholar

Chakraborty PS, Kumar R, Tripathi M, Das CJ and Bal C: Detection of brain metastasis with 68Ga-labeled PSMA ligand PET/CT: A novel radiotracer for imaging of prostate carcinoma. Clin Nucl Med. 40:328–329. 2015.PubMed/NCBI View Article : Google Scholar

Calais J, Zhu S, Hirmas N, Eiber M, Hadaschik B, Stuschke M, Herrmann K, Czernin J, Kishan AU, Nickols NG, et al: Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: Study protocol. BMC Cancer. 21(512)2021.PubMed/NCBI View Article : Google Scholar

Calais J, Zhu S, Hirmas N, Eiber M, Hadaschik BA, Stuschke M, Herrmann K, Czernin J, Kishan AU, Nickols NG, et al: Phase III randomized trial of PSMA PET prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: Study protocol NCT04457245. J Clin Oncol. 39 (Suppl 6)(TPS172)2021.PubMed/NCBI View Article : Google Scholar

Calais J, Kishan AU, Cao M, Fendler WP, Eiber M, Herrmann K, Ceci F, Reiter RE, Rettig MB, Hegde JV, et al: Potential impact of ⁶⁸Ga-PSMA-11 PET/CT on the planning of definitive radiation therapy for prostate cancer. J Nucl Med. 59:1714–1721. 2018.PubMed/NCBI View Article : Google Scholar

Sonni I, Eiber M, Fendler WP, Alano RM, Vangala SS, Kishan AU, Nickols N, Rettig MB, Reiter RE, Czernin J and Calais J: Impact of ⁶⁸Ga-PSMA-11 PET/CT on staging and management of prostate cancer patients in various clinical settings: A prospective single-center study. J Nucl Med. 61:1153–1160. 2020.PubMed/NCBI View Article : Google Scholar

Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES, Rowe SP, Ross AE, Gorin MA, Deville C, et al: Outcomes of observation vs. stereotactic ablative radiation for oligometastatic prostate cancer: The ORIOLE phase 2 randomized clinical trial. JAMA Oncol. 6:650–659. 2020.PubMed/NCBI View Article : Google Scholar

Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G, Wester HJ, Heck M, Kübler H, Beer AJ, et al: Diagnostic efficacy of (68)gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J Urol. 195:1436–1443. 2016.PubMed/NCBI View Article : Google Scholar

Zarbiv Y, Peerless Y, Wygoda M, Orevi M, Meir K, Gofrit ON, Yutkin V and Frank S: Real-world Israeli single institution experience with PET-PSMA for staging of patients with clinically staged localized prostate carcinoma. Cancer Rep (Hoboken). 4(e1386)2021.PubMed/NCBI View Article : Google Scholar

Onal C, Torun N, Oymak E, Guler OC, Reyhan M and Yapar AF: Retrospective correlation of ⁶⁸ga-psma uptake with clinical parameters in prostate cancer patients undergoing definitive radiotherapy. Ann Nucl Med. 34:388–396. 2020.PubMed/NCBI View Article : Google Scholar

Uprimny C, Kroiss AS, Decristoforo C, Fritz J, von Guggenberg E, Kendler D, Scarpa L, di Santo G, Roig LG, Maffey-Steffan J, et al: ⁶⁸Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and gleason score predict the intensity of tracer accumulation in the primary tumour. Eur J Nucl Med Mol Imaging. 44:941–949. 2017.PubMed/NCBI View Article : Google Scholar

Ergül N, Yilmaz Güneş B, Yücetaş U, Toktaş MG and Çermik TF: 68Ga-PSMA-11 PET/CT in newly diagnosed prostate adenocarcinoma. Clin Nucl Med. 43:e422–e427. 2018.PubMed/NCBI View Article : Google Scholar

Amiel T, Würnschimmel C, Heck M, Horn T, Nguyen N, Budäus L, Knipper S, Wenzel M, Rauscher I, Eiber M, et al: Regional lymph node metastasis on prostate specific membrane antigen positron emission tomography correlates with decreased biochemical recurrence-free and therapy-free survival after radical prostatectomy: A retrospective single-center single-arm observational study. J Urol. 205:1663–1670. 2021.PubMed/NCBI View Article : Google Scholar

Hotta M, Gafita A, Czernin J and Calais J: Outcome of patients with PSMA PET/CT screen failure by VISION criteria and treated with ¹⁷⁷Lu-PSMA therapy: A multicenter retrospective analysis. J Nucl Med. 63:1484–1488. 2022.PubMed/NCBI View Article : Google Scholar

Seifert R, Seitzer K, Herrmann K, Kessel K, Schäfers M, Kleesiek J, Weckesser M, Boegemann M and Rahbar K: Analysis of PSMA expression and outcome in patients with advanced prostate cancer receiving ¹⁷⁷Lu-PSMA-617 radioligand therapy. Theranostics. 10:7812–7820. 2020.PubMed/NCBI View Article : Google Scholar

Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, Holland-Letz T, Hadaschik BA, Giesel FL, Debus J and Haberkorn U: Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 41:11–20. 2014.PubMed/NCBI View Article : Google Scholar

Morigi JJ, Stricker PD, van Leeuwen PJ, Tang R, Ho B, Nguyen Q, Hruby G, Fogarty G, Jagavkar R, Kneebone A, et al: Prospective comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med. 56:1185–1190. 2015.PubMed/NCBI View Article : Google Scholar

Hope TA, Goodman JZ, Allen IE, Calais J, Fendler WP and Carroll PR: Metaanalysis of ⁶⁸Ga-PSMA-11 PET accuracy for the detection of prostate cancer validated by histopathology. J Nucl Med. 60:786–793. 2019.PubMed/NCBI View Article : Google Scholar

McCarthy M, Francis R, Tang C, Watts J and Campbell A: A multicenter prospective clinical trial of ⁶⁸gallium PSMA HBED-CC PET-CT restaging in biochemically relapsed prostate carcinoma: Oligometastatic rate and distribution compared with standard imaging. Int J Radiat Oncol Biol Phys. 104:801–808. 2019.PubMed/NCBI View Article : Google Scholar

Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, Nguyen HG, Reiter RE, Rettig MB, Okamoto S, et al: Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: A prospective single-arm clinical trial. JAMA Oncol. 5:856–863. 2019.PubMed/NCBI View Article : Google Scholar

Hofman MS, Hicks RJ, Maurer T and Eiber M: Prostate-specific membrane antigen PET: Clinical utility in prostate cancer, normal patterns, pearls, and pitfalls. Radiographics. 38:200–217. 2018.PubMed/NCBI View Article : Google Scholar

Rischpler C, Beck TI, Okamoto S, Schlitter AM, Knorr K, Schwaiger M, Gschwend J, Maurer T, Meyer PT and Eiber M: ⁶⁸Ga-PSMA-HBED-CC uptake in cervical, celiac, and sacral ganglia as an important pitfall in prostate cancer PET imaging. J Nucl Med. 59:1406–1411. 2018.PubMed/NCBI View Article : Google Scholar

Fendler WP, Ferdinandus J, Czernin J, Eiber M, Flavell RR, Behr SC, Wu IK, Lawhn-Heath C, Pampaloni MH, Reiter RE, et al: Impact of ⁶⁸Ga-PSMA-11 PET on the management of recurrent prostate cancer in a prospective single-arm clinical trial. J Nucl Med. 61:1793–1799. 2020.PubMed/NCBI View Article : Google Scholar

Calais J, Fendler WP, Eiber M, Gartmann J, Chu FI, Nickols NG, Reiter RE, Rettig MB, Marks LS, Ahlering TE, et al: Impact of ⁶⁸Ga-PSMA-11 PET/CT on the management of prostate cancer patients with biochemical recurrence. J Nucl Med. 59:434–441. 2018.PubMed/NCBI View Article : Google Scholar

Rousseau C, Le Thiec M, Ferrer L, Rusu D, Rauscher A, Maucherat B, Frindel M, Baumgartner P, Fleury V, Denis A, et al: Preliminary results of a ⁶⁸Ga-PSMA PET/CT prospective study in prostate cancer patients with occult recurrence: Diagnostic performance and impact on therapeutic decision-making. Prostate. 79:1514–1522. 2019.PubMed/NCBI View Article : Google Scholar

Calais J, Czernin J, Fendler WP, Elashoff D and Nickols NG: Randomized prospective phase III trial of ⁶⁸Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]. BMC Cancer. 19(18)2019.PubMed/NCBI View Article : Google Scholar

Kratochwil C, Giesel FL, Eder M, Afshar-Oromieh A, Benešová M, Mier W, Kopka K and Haberkorn U: [⁷⁷Lu] Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 42:987–988. 2015.PubMed/NCBI View Article : Google Scholar

Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schäfers M, Essler M, Baum RP, Kulkarni HR, Schmidt M, Drzezga A, et al: German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med. 58:85–90. 2017.PubMed/NCBI View Article : Google Scholar

Heck MM, Tauber R, Schwaiger S, Retz M, D'Alessandria C, Maurer T, Gafita A, Wester HJ, Gschwend JE, Weber WA, et al: Treatment outcome, toxicity, and predictive factors for radioligand therapy with ¹⁷⁷Lu-PSMA-I&T in metastatic castration-resistant prostate cancer. Eur Urol. 75:920–926. 2019.PubMed/NCBI View Article : Google Scholar

Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, Iravani A, Kong G, Ravi Kumar A, Murphy DG, et al: [¹⁷⁷Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): A single-centre, single-arm, phase 2 study. Lancet Oncol. 19:825–833. 2018.PubMed/NCBI View Article : Google Scholar

Violet J, Sandhu S, Iravani A, Ferdinandus J, Thang SP, Kong G, Kumar AR, Akhurst T, Pattison DA, Beaulieu A, et al: Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center phase II prospective trial of ¹⁷⁷Lu-PSMA-617 theranostics in metastatic castration-resistant prostate cancer. J Nucl Med. 61:857–865. 2020.PubMed/NCBI View Article : Google Scholar

Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Ng S, et al: [¹⁷⁷Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): A randomised, open-label, phase 2 trial. Lancet. 397:797–804. 2021.PubMed/NCBI View Article : Google Scholar

Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N, El-Haddad G, et al: Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 385:1091–1103. 2021.PubMed/NCBI View Article : Google Scholar

Khreish F, Ghazal Z, Marlowe RJ, Rosar F, Sabet A, Maus S, Linxweiler J, Bartholomä M and Ezziddin S: 177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY study). Eur J Nucl Med Mol Imaging. 49:1075–1085. 2022.PubMed/NCBI View Article : Google Scholar

Privé BM, Janssen MJR, van Oort IM, Muselaers CHJ, Jonker MA, van Gemert WA, de Groot M, Westdorp H, Mehra N, Verzijlbergen JF, et al: Update to a randomized controlled trial of lutetium-177-PSMA in oligo-metastatic hormone-sensitive prostate cancer: The BULLSEYE trial. Trials. 22(768)2021.PubMed/NCBI View Article : Google Scholar

Erdogan M, Sengul SS, Cetin B, Avcı M, Yagci S, Ozkoç I, Barikan DE and Yildiz M: The role of Ga⁶⁸ PSMA PET/CT imaging in Lu¹⁷⁷ PSMA treatment planning in metastatic castration-resistant prostate cancer. Ann Nucl Med. 36:562–569. 2022.PubMed/NCBI View Article : Google Scholar

Peters SMB, Hofferber R, Privé BM, de Bakker M, Gotthardt M, Janssen M, de Lange F, Muselaers CHJ, Mehra N, Witjes JA, et al: [⁶⁸Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [¹⁷⁷Lu]Lu-PSMA-617 treatment. Eur J Nucl Med Mol Imaging. 49:1101–1112. 2022.PubMed/NCBI View Article : Google Scholar

Paschalis A, Sheehan B, Riisnaes R, Rodrigues DN, Gurel B, Bertan C, Ferreira A, Lambros MBK, Seed G, Yuan W, et al: Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer. Eur Urol. 76:469–478. 2019.PubMed/NCBI View Article : Google Scholar

Lückerath K, Wei L, Fendler WP, Evans-Axelsson S, Stuparu AD, Slavik R, Mona CE, Calais J, Rettig M, Reiter RE, et al: Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer. EJNMMI Res. 8(96)2018.PubMed/NCBI View Article : Google Scholar

Rosar F, Dewes S, Ries M, Schaefer A, Khreish F, Maus S, Bohnenberger H, Linxweiler J, Bartholomä M, Ohlmann C and Ezziddin S: New insights in the paradigm of upregulation of tumoral PSMA expression by androgen receptor blockade: Enzalutamide induces PSMA upregulation in castration-resistant prostate cancer even in patients having previously progressed on enzalutamide. Eur J Nucl Med Mol Imaging. 47:687–694. 2020.PubMed/NCBI View Article : Google Scholar

Grignon DJ, Caplan R, Sarkar FH, Lawton CA, Hammond EH, Pilepich MV, Forman JD, Mesic J, Fu KK, Abrams RA, et al: p53 status and prognosis of locally advanced prostatic adenocarcinoma: A study based on RTOG 8610. J Natl Cancer Inst. 89:158–165. 1997.PubMed/NCBI View Article : Google Scholar

Stuparu AD, Capri JR, Meyer CAL, Le TM, Evans-Axelsson SL, Current K, Lennox M, Mona CE, Fendler WP, Calais J, et al: Mechanisms of resistance to prostate-specific membrane antigen-targeted radioligand therapy in a mouse model of prostate cancer. J Nucl Med. 62:989–995. 2021.PubMed/NCBI View Article : Google Scholar

Nadal R, Schweizer M, Kryvenko ON, Epstein JI and Eisenberger MA: Small cell carcinoma of the prostate. Nat Rev Urol. 11:213–219. 2014.PubMed/NCBI View Article : Google Scholar

Parghane R and Basu S: Small cell transformation of metastatic prostate adenocarcinoma diagnosed by dual-tracer PET/CT (⁶⁸Ga-PSMA and ¹⁸F-FDG): Potential clinical utility in therapeutic decision making and treatment monitoring. J Nucl Med Technol. 47:85–87. 2019.PubMed/NCBI View Article : Google Scholar

Hope TA, Truillet C, Ehman EC, Afshar-Oromieh A, Aggarwal R, Ryan CJ, Carroll PR, Small EJ and Evans MJ: 68Ga-PSMA-11 PET imaging of response to androgen receptor inhibition: First human experience. J Nucl Med. 58:81–84. 2017.PubMed/NCBI View Article : Google Scholar

Schuster DM: SPOTLIGHT Study Group. Detection rate of ¹⁸F-rhPSMA-7.3 PET in patients with suspected prostate cancer recurrence: Results from a phase 3, prospective, multicenter study (SPOTLIGHT). J Clin Oncol. 40 (Suppl)(S9)2022.PubMed/NCBI View Article : Google Scholar

Pienta KJ, Gorin MA, Rowe SP, Carroll PR, Pouliot F, Probst S, Saperstein L, Preston MA, Alva AS, Patnaik A, et al: A phase 2/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET/CT with ¹⁸F-DCFPyL in prostate cancer patients (OSPREY). J Urol. 206:52–61. 2021.PubMed/NCBI View Article : Google Scholar

Morris MJ, Rowe SP, Gorin MA, Saperstein L, Pouliot F, Josephson D, Wong JYC, Pantel AR, Cho SY, Gage KL, et al: Diagnostic performance of ¹⁸F-DCFPyL-PET/CT in men with biochemically recurrent prostate cancer: Results from the CONDOR phase III, multicenter study. Clin Cancer Res. 27:3674–3682. 2021.PubMed/NCBI View Article : Google Scholar

Olivier P, Giraudet AL, Skanjeti A, Merlin C, Weinmann P, Rudolph I, Hoepping A and Gauthé M: Phase III study of ¹⁸F-PSMA-1007 versus ¹⁸F-fluorocholine PET/CT for localization of prostate cancer biochemical recurrence: A prospective, randomized, cross-over, multicenter study. J Nucl Med: Nov 23, 2022 (Epub ahead of print).

Hoffmann MA, Müller-Hübenthal J, Rosar F, Fischer N, von Eyben FE, Buchholz HG, Wieler HJ and Schreckenberger M: Primary staging of prostate cancer patients with [¹⁸F]PSMA-1007 PET/CT compared with [⁶⁸Ga]Ga-PSMA-11 PET/CT. J Clin Med. 11(5064)2022.PubMed/NCBI View Article : Google Scholar

Müller C, Umbricht CA, Gracheva N, Tschan VJ, Pellegrini G, Bernhardt P, Zeevaart JR, Köster U, Schibli R and van der Meulen NP: Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer. Eur J Nucl Med Mol Imaging. 46:1919–1930. 2019.PubMed/NCBI View Article : Google Scholar